Peer-reviewedCC BYFrontiers in cell and developmental biology
HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges
- 1Cancer Center, The First Hospital of Jilin University , ,
- 2Department of Endocrinology and Metabolism, The First Hospital of Jilin University , , ,
- 3School of Medicine, Hebei University of Engineering , ,
Related
- Disease-specific gut microbiota–metabolite–immune networks in hematologic disorders: mechanisms, causal support, and translational strategies
- Overcoming the nuclear barrier in nonviral gene therapy: mechanisms, carrier design, and translational perspectives on NLS peptide and DNA targeting sequence strategies.
- Stem Cell and EV/sEV Strategies for Neuroimmune Niche Reprogramming in Selected CNS Disorders: Mechanisms, Engineered Delivery, and Translational Readiness.
- The vascular–immune interface in breast cancer: normalization strategies, combination therapy, and biomarkers
- Modulating the NLRP3/IL-1β Axis in Age-Related Atherosclerosis: Natural Products, Molecular Mechanisms, and Translational Perspectives—A Narrative Review
BibTeX
@article{liu2026hdac,
title = {{HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges}},
author = {Kun-Yao Liu and Xiang Zhao and Jia-Hui Liu and Mu-Nan Li and Hai-Ying Cui and Zhen Wang and Xin Zhou},
journal = {Frontiers in cell and developmental biology},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13658942},
note = {CC BY},
}
RIS
TY - JOUR
TI - HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges
AU - Kun-Yao Liu
AU - Xiang Zhao
AU - Jia-Hui Liu
AU - Mu-Nan Li
AU - Hai-Ying Cui
AU - Zhen Wang
AU - Xin Zhou
PY - 2026
DA - 2026/10/16
JO - Frontiers in cell and developmental biology
UR - https://europepmc.org/article/PMC/PMC13658942
SN - 2296-634X
ER -